Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients

Journal of Endocrinological Investigation

Volumn 38, Issue 1, 2015, Pages 81-89

  Russo, G T ^a   Labate, A M ^a   Giandalia, A ^a   Romeo, E L ^a   Villari, P ^a   Alibrandi, A ^b   Perdichizzi, G ^a   Cucinotta, D ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Blood pressure; Lipids; Liraglutide; Type 2 diabetes; Visceral adiposity index

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; SARTAN DERIVATIVE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; ASTHENIA; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VISCERAL ADIPOSITY INDEX; VOMITING; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; OBESITY, ABDOMINAL; OUTPATIENT DEPARTMENT; PHYSIOLOGY; RISK FACTOR; TIME FACTOR;

ADIPOSITY; ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923887216     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0163-9     Document Type: Article

References (34)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053
2. Buse JB, Ginsberg HN, Bakris GL et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115:114-126
3. Liu SC, Tu YK, Chien MN, Chien KL (2012) Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 14:810-820
4. Drucker DJ, Nauck MA (2006) The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 11(368):1696-1705
5. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771
6. Vilsbøll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes Obes Metab 14(Suppl 2):41-49
7. Marre M, Shaw J, Brändle M et al (2009) LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
8. Nauck M, Frid A, Hermansen K et al (2013) Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15:204-212
9. Garber A (2011) Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13:348-356
10. Zinman B, Gerich J, Buse JB et al (2009) LEAD-4 Study investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32:1224-1230
11. Russell-Jones D, Vaag A, Schmitz O et al (2009) Liraglutide effect and action in diabetes 5 (LEAD-5) met + SU study group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52:2046-2055
12. Buse JB, Rosenstock J, Sesti G et al (2009) LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
13. Klonoff DC, Buse JB, Nielsen LL et al (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286
14. Wang B, Zhong J, Lin H et al (2013) Blood pressure -lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 15:737-749
15. Inoue K, Maeda N, Kashine S et al (2011) Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 10:109
16. Amato MC, Giordano C, Galia M, AlkaMeSy Study Group et al (2010) Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920-922
17. Mohammadreza B, Farzad H, Davoud K, Fereidoun Prof AF (2012) Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: tehran lipid and glucose study. Cardiovasc Diabetol 11:20
18. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1):e001986
19. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA) http://clinicaltrials.gov/show/NCT01147250
20. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499-502
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461-470
22. McCarthy MI (2010) Genomics, type 2 diabetes, and obesity. N Engl J Med 363:2339-2350
23. Niswender K, Pi-Sunyer X, Buse J et al (2013) Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 15:42-54
24. Fonseca V, Madsbad S, Falahati A et al (2009) Once-daily human GLP-1 analog liraglutide reduces systolic BP: a meta-analysis of 6 clinical trials (Abstract). Diabetes 58(Suppl):A146
25. Anagnostis P, Athyros VG, Adamidou F et al (2011) Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 13:302-312
26. Wang B, Ni Y, Zhong J, Sun F (2012) Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension. J Diabetes 4:22-29
27. Choe HM, Townsend KA, Blount G, Lo CH, Sadowski L, Standiford CJ (2007) Treatment and control of blood pressure in patients with diabetes mellitus. Am J Health Syst Pharm 64:97-103
28. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T (2012) The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 9:209-222
29. Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P (2012) Clinical use of liraglutide in type 2 diabetes and its effect on cardiovascular risk factors. Endocrine Practice 18:140-145
30. Vilsbøll T, Zdravkovic M, Le Thi T et al (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608-1610
31. Stein EA, Black DM (2002) Lipoprotein changes with statins. Curr Atheroscler Rep 4:14-18
32. Chehade JM, Alcalde R, Naem E, Mooradian AD, Wong NC, Haas MJ (2013) Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells. Metabolism 62:265-274
33. Amato MC, Giordano C, Pitrone M, Galluzzo A (2011) Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 10:183
34. Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM (2013) A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther 4:147-151